Related Experiment Videos
Limited knowledge on progestogen-only contraception and risk of venous thromboembolism
Annica Bergendal1, Viveca Odlind, Ingemar Persson
1Department of Medicine, Centre for Pharmacoepidemiology, Karolinska Institutet, Solna, 17176 Stockholm, Sweden. annica.bergendal@ki.se
Objective:
To assess the current knowledge concerning progestogen-only contraception (POC) and risks of venous thromboembolism (VTE).
Design And Setting:
Systematic review of the literature on observational and analytical studies reporting risk estimates for VTE in women exposed to POCs.
Methods And Main Outcome Measures:
We performed a computerized literature search in the Pub Med, Embase, and the Cochrane Library for studies published between 1966 and February 13, 2008. Based on the evaluated studies we calculated an overall risk estimate for VTE in association with POC.
Results:
Four case-control studies and one cohort study were included. Of the case-control studies, three reported an increased risk and one a decreased risk of VTE. The cohort study found divergent results depending on the type of statistical analysis used. None of the results was statistically significant. The overall odds ratio for POC-associated VTE in the four case-control studies was 1.45 (95% CI=0.92-2.26).
Conclusions:
The risk of VTE associated with use of POCs is poorly investigated. The slightly elevated overall risk estimate might suggest an association between POC and an increased risk for VTE. The results must, however, be interpreted with caution due to the possibility of residual confounding. Well-designed studies with sufficient statistical power to evaluate risks of VTE with POC are warranted.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Birth Control Methods
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis I: Introduction
Intrauterine Drug Delivery Systems
Anticoagulant Drugs: Low-Molecular-Weight Heparins